Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 5,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control/Placebo group Clear all

Conditions: Alzheimer's Disease
Interventions: Placebo, Idalopirdine; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 50 Years and older
Enrollment: 933 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 46
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 40 more

Conditions: Aneurysmal Subarachnoid Hemorrhage
Interventions: Gabapentin, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Fatty Liver, Non-Alcoholic Steatohepatitis
Interventions: Vitamin E [(all-rac)-α-tocopheryl acetate], Omega-3 fatty acid (DHA EE), Omega-3 fatty acid (DHA EE) & Vitamin E [(all-rac)-α-tocopheryl acetate], Placebo; Dietary Supplement · Combination Product · Other
Lead sponsor: Naga P. Chalasani; Other
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Chandler, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 10 more

Conditions: Infertility, Infertility, Female, Oocyte Retrieval, Postoperative Pain, Embryo Transfer
Interventions: Ketorolac (Toradol), Placebo (saline); Drug · Other
Lead sponsor: Shady Grove Fertility Reproductive Science Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Rockville, Maryland • Fairfax, Virginia

Conditions: Asthma
Interventions: Fluticasone propionate pressurized metered dose inhaler, Flovent HFA pressurized metered dose inhaler, Placebo pressurized metered dose inhaler; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,902 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Postherpetic Neuralgia
Interventions: Z160, Placebo; Drug
Lead sponsor: Zalicus; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 53
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 50 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: OPDC-34712, Placebo, Stimulant Therapy; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 35
States / cities: Little Rock, Arkansas • Beverly Hills, California • Irvine, California + 32 more

Conditions: Cervical Dystonia
Interventions: Corabotase, Placebo; Biological · Other
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: Tucson, Arizona • Fountain Valley, California • Loma Linda, California + 7 more

Conditions: Coronary Disease, Heart Valve Diseases
Interventions: CTI-01 (ethyl pyruvate); Drug
Lead sponsor: Critical Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 17
States / cities: Laguna Hills, California • Los Angeles, California • San Francisco, California + 14 more

Conditions: Immune Thrombocytopenia
Interventions: Rilzabrutinib, Placebo; Drug
Lead sponsor: Principia Biopharma, a Sanofi Company; Industry
Eligibility: 10 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 17
States / cities: Los Angeles, California • San Francisco, California • Torrance, California + 13 more

Conditions: Major Depressive Disorder, Anxiety Disorders
Interventions: Hydrocortisone; Drug
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Austin, Texas

Conditions: Hot Flushes, Menopause, Premature, Obesity, Vitamin D Deficiency
Interventions: Vitamin D, Placebo; Dietary Supplement · Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Partial Seizures, Epilepsies, Partial
Interventions: pregabalin, placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 26
States / cities: Northport, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 15 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Sotagliflozin (SAR439954), Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 56
States / cities: Tucson, Arizona • Anaheim, California • Canoga Park, California + 46 more

Conditions: Presbyopia
Interventions: Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine Ophthalmic Topical Cream, Dose 2, Pilocarpine Ophthalmic Topical Cream, Dose 3, Placebo Ophthalmic Topical Cream; Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 40 Years to 55 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 10
States / cities: Chandler, Arizona • Sun City, Arizona • Glendale, California + 7 more

Conditions: Healthy
Interventions: Beetroot Juice, Placebo Control; Dietary Supplement
Lead sponsor: Baylor University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Dallas, Texas • Waco, Texas

Conditions: Functional Constipation in Children Ages 6-17 Years
Interventions: Placebo, LIN Dose A, LIN Dose B, LIN Dose C, LIN 145 µg; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 60
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 51 more

Conditions: Ebola
Interventions: Ad26.ZEBOV, MVA-BN-Filo, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 974 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 7
States / cities: Mobile, Alabama • Tempe, Arizona • Lexington, Kentucky + 4 more

Conditions: Hypertension
Interventions: valsartan+amlodipine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Cancer Cachexia
Interventions: RC-1291, placebo; Drug
Lead sponsor: Helsinn Therapeutics (U.S.), Inc; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 17
States / cities: Glendale, Arizona • Encinitas, California • Santa Monica, California + 13 more

Conditions: Atopic Dermatitis
Interventions: Tilrekimig, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 14
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 11 more

Conditions: HIV Infections
Interventions: MVA-CMDR, Placebo; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 40 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Full-thickness Rotator Cuff Tear
Interventions: Arthroscopic Rotator Cuff Repair, Ropivacaine, Saline; Procedure · Drug
Lead sponsor: Orlando Health, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Healthy
Interventions: AZD9742, Placebo to match AZD9742; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 23 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil

Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage

Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)

Assessing Ketorolac (Toradol) at Oocyte Retrieval

Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg

Efficacy and Safety Study of Z160 in Subjects With Postherpetic Neuralgia

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder

A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults

CTI-01 (Ethyl Pyruvate) Safety and Complication Prevention in Cardiac Surgery Patients on Cardiopulmonary Bypass (CPB)

Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration

The Role of Vitamin D in Menopause: Relationship to Menopausal Symptoms in Body Composition

Once-A-Day Pregabalin For Partial Seizures

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia

Beetroot Juice for Boosting Immunity During a Time of Stress.

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

One Year Study to Evaluate the Safety of the Combination of Valsartan and Amlodipine in Patients With Hypertension

Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema

Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

Efficacy of Continuous Infusion Ropivacaine Interscalene Blocks

This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects